Medpace Holdings, Inc. — Form 8-K
Filed October 21, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
Medpace reported Q3 2026 revenue of $716.0M (+8.5% YoY), net income of $137.5M ($4.84 diluted EPS), and EBITDA of $172.1M (+16.0% YoY). Net new business awards were $873.4M (+10.6% YoY). The Board terminated the existing repurchase authorization ($527M remaining) and approved a new $1.0B buyback program through December 31, 2028. Full-year 2026 guidance: revenue $2.835–$2.855B, net income $514–$524M, EBITDA $638–$652M.
Why this rating
Solid organic growth and margin expansion, but at company's historical pace; $1B buyback is ~14% of market cap but routine for cash-generative firms.
See more from October 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.